0001213900-24-042944.txt : 20240514 0001213900-24-042944.hdr.sgml : 20240514 20240514161250 ACCESSION NUMBER: 0001213900-24-042944 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240514 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 24944484 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea0206088-8k_inmed.htm CURRENT REPORT
false 0001728328 A1 BC CA 0001728328 2024-05-14 2024-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 14, 2024

 

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

   V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On May 14, 2024, the Company announced financial results and business update for the third quarter of the fiscal year 2024, which ended March 31, 2024.

 

The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description

99.1 

   News release, dated May 14, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: May 14, 2024 By: /s/ Netta Jagpal 
   

Chief Financial Officer

 

 

2

 

 

 EX-99.1 2 ea020608801ex99-1_inmed.htm NEWS RELEASE, DATED MAY 14, 2024

Exhibit 99.1

 

 

NASDAQ: INM

 

Suite 310-815 W. Hastings St.

Vancouver, BC, Canada V6C 1B4

Tel: +1.604.669.7207

Email: info@inmedpharma.com

www.inmedpharma.com

 

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

 

●Reported positive preclinical data in both its Alzheimer’s and dry AMD programs

 

●Closed Fiscal Q3 with cash position of US$7.9 million

 

Vancouver, BC – May 14, 2024 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced financial results and business update for the third quarter of the fiscal year 2024, which ended March 31, 2024. 

 

The Company’s full financial statements and related MD&A for the third quarter ended March 31, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

 

Eric A. Adams, InMed President and CEO, commented, “The third quarter of fiscal year 2024 was another positive quarter for the Company as we continue to make exciting progress in our pharmaceutical pipeline and deliver steady growth in our commercial business. Last month we announced important updates in our two preclinical programs in the treatment of Alzheimer’s disease (“ALZ”) and dry Age-related Macular Degeneration (“dry AMD”). Both programs utilize proprietary small molecule drug candidates activating both the CB1 / CB2 receptors as well as other disease-relevant receptors. We are highly encouraged by the positive findings and we are committed to further advancing our research in these two highly underserved indications.”

 

Adams continued, “Revenues from the BayMedica commercial business remain consistent with the previous quarter and BayMedica operated as a profitable commercial business unit in the current quarter. We remain optimistic for the sector as more brands start to incorporate rare cannabinoids into their product portfolios.”

 

Business update

 

Pharmaceutical Development Programs

 

INM-901: A multipronged approach in treatment of Alzheimer’s disease.

 

INM-901 is a proprietary small molecule drug candidate being developed as a potential treatment for ALZ employing multiple mechanisms of actions. On April 4, 2024, the Company announced additional preclinical data demonstrating INM-901’s positive pharmacological effects. Results included:

 

●INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and impacts the PPAR signaling pathway;
   
●INM-901 demonstrates reduced neuroinflammation and improved neuronal function; and
   
●mRNA data from INM-901 preclinical studies support the observations made in the previously released behavior studies in locomotor activity, cognition and memory.

 

InMed continues to accelerate the development of its ALZ program, with long-term behavioural and mechanism of action / receptor interaction studies currently underway. Data read-out expected in calendar 3Q 2024.

 

Additionally, the Company recently announced the addition of Dr. David G. Morgan, a leader in neurodegenerative disease, to its Scientific Advisory Board (“SAB”), reinforcing the Company’s commitment to advancing it’s INM-901 program.

 

 

 

 

INM-089: Neuroprotection in the treatment of dry AMD

 

INM-089 is another proprietary small molecule drug candidate being studied in the treatment of Age-related Macular Degeneration (“AMD”). In April, the Company announced additional preclinical data for INM-089 further demonstrating positive pharmacological effects. Results from INM-089 preclinical studies included:

 

●Data indicates that INM-089 may be more effective as a therapeutic treatment for dry AMD compared to neovascular, or wet, AMD;

 

●More specifically, data suggests INM-089 may be an important candidate for geographic atrophy (“GA”) which is common in more advanced cases of dry AMD;

 

●Enhanced neuroprotection of photoreceptors as well as improved photoreceptor function;

 

●Improved integrity of retinal pigment epithelium; and

 

●Reduction in extracellular autofluorescent deposits, a hallmark of dry AMD.

 

The Company has strategically prioritized the utilization of its proprietary small molecule drug candidates in its drug development initiatives, resulting in the INM-089 program for the treatment of dry AMD taking precedence over the INM-088 program in the treatment of glaucoma. Therefore, the Company will not be advancing INM-088 in the immediate future. Notably, the initial research and data from the INM-088 program have played an instrumental role in shaping the development of INM-089 program.

 

BayMedica Commercial Business

 

BayMedica revenues were $3.3 million for the nine months ended March 31, 2024, compared with $1.8 million for the nine months ended March 31, 2023, representing 83% growth over the same period last year. Quarter over quarter revenue has remained flat this period with sales of $1.2 million, same as the previous quarter. BayMedica operated as a profitable business unit this quarter and continues to make progress lowering manufacturing costs that should incrementally improve margins over time. While we are optimistic about the long-term growth potential in the rare cannabinoids sector, we expect revenue to fluctuate in future quarters.

 

Financial and Corporate Highlights:

 

●Net loss was $5.7 million for the quarter ended March 31, 2024, compared to a net loss of $7.6 million in the same period last year.

 

●Research and development and patents expenses were $2.6 million for the nine months ended March 31, 2024, compared with $3.1 million for the nine months ended March 31, 2023.

 

●General and administrative expenses were $4 million for the nine months ended March 31, 2024, compared with $4.4 million for the same period last year.

 

●As of March 31, 2023, the Company’s cash, cash equivalents and short-term investments were $7.6 million, which compares to $8.9 million on June 30, 2023.

 

Based on current forecasts, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure requirements into the fourth quarter of calendar year 2024, depending on the level and timing of realizing BayMedica revenues from the sale of products in the Health & Wellness sector as well as the level and timing of our operating expenses.

 

Ms. Alexandra D.J. Mancini, Senior Vice President, Clinical & Regulatory Affairs, provided notice to the Company and the Company’s Board of Directors of her intention to retire from her position, effective June 30, 2024. Ms. Mancini intends to continue in a consultancy capacity to ensure a smooth transition of both the INM-755 program and ongoing regulatory matters. The Company would like to thank Ms. Mancini for her significant, valuable contributions, and leadership during her tenure with InMed and wish her all the best in her retirement. We congratulate her on a tremendous career in the biotech industry, having played an important role in developing and bringing to market several pharmaceutical products in many disease areas.

 

2

 

 

Table 1. InMed Pharmaceuticals Inc.

 

CONDENSED CONSOLIDATED BALANCE SHEETS

Expressed in U.S. Dollars

 
  

March 31,

2024

   June 30, 
   (unaudited)   2023 
  

$

  

$

 

ASSETS

        
Current        
Cash and cash equivalents   7,600,598    8,912,517 
Short-term investments   43,085    44,422 
Accounts receivable, net of allowance for credit losses of $66,775 in 2024 and 2023   207,681    260,399 
Inventories   1,193,952    1,616,356 
Prepaids and other current assets   1,018,686    498,033 
Total current assets   10,064,002    11,331,727 
           
Non-Current          
Property, equipment and ROU assets, net   1,370,969    723,426 
Intangible assets, net   1,823,745    1,946,279 
Other assets   100,000    104,908 
Total Assets   13,358,716    14,106,340 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
Current          
Accounts payable and accrued liabilities   1,183,285    1,608,735 
Current portion of lease obligations   345,545    375,713 
Deferred rent   -    16,171 
Total current liabilities   1,528,830    2,000,619 
           
Non-current          
Lease obligations, net of current portion   725,236    15,994 
Total Liabilities   2,254,066    2,016,613 
Commitments and Contingencies (Note 11)          
           
Shareholders’ Equity          
Common shares, no par value, unlimited authorized shares:          
6,344,970 (June 30, 2023 - 3,328,191) issued and outstanding   80,606,863    77,620,252 
Additional paid-in capital   37,507,306    35,741,115 
Accumulated deficit   (107,138,088)   (101,400,209)
Accumulated other comprehensive income   128,569    128,569 
Total Shareholders’ Equity   11,104,650    12,089,727 
Total Liabilities and Shareholders’ Equity   13,358,716    14,106,340 
Related Party Transactions (Note 12)          
Subsequent Events (Note 13)          

 

3

 

 

Table 2. InMed Pharmaceuticals Inc.

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

Expressed in U.S. Dollars

 

   For the Three Months Ended
31-Mar		   For the Nine Months Ended
31-Mar		 
   2024   2023   2024   2023 
   $   $   $   $ 
                
Sales   1,172,601    1,033,925    3,314,663    1,824,496 
Cost of sales   883,143    841,414    2,416,417    1,415,068 
Inventory write-down   -    -    263,404    576,772 
Gross profit   289,458    192,511    634,842    (167,344)
                     
Operating Expenses                    
Research and development and patents   656,764    878,303    2,558,648    3,108,312 
General and administrative   1,374,095    1,412,727    4,036,784    4,438,083 
Amortization and depreciation   54,767    50,689    164,833    148,786 
Foreign exchange loss   48,156    2,733    36,717    79,287 
Total operating expenses   2,133,782    2,344,452    6,796,982    7,774,468 
                     
Other Income (Expense)                    
Interest and other income   121,458    155,497    424,261    343,881 
Loss before income taxes   (1,722,866)   (1,996,444)   (5,737,879)   (7,597,931)
                     
Tax expense   -    (1,500)   -    (11,300)
Net loss for the period   (1,722,866)   (1,997,944)   (5,737,879)   (7,609,231)
                     
Net loss per share for the period                    
Basic and diluted   (0.18)   (0.60)   (0.82)   (3.53)
Weighted average outstanding common shares                    
Basic and diluted   9,612,973    3,328,191    6,961,938    2,156,283 

 

4

 

 

Table 3. InMed Pharmaceuticals Inc.

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

Expressed in U.S. Dollars

 

   March 31,   March 31, 
   2024   2023 
  

$

  

$

 
Cash provided by (used in):        
Operating Activities        
Net loss   (5,737,879)   (7,609,231)
Items not requiring cash:          
Amortization and depreciation   164,833    148,786 
Share-based compensation   98,760    237,675 
Amortization of right-of-use assets   287,824    296,239 
Interest income on short-term investments   (1,271)   (392)
Unrealized foreign exchange loss   2,607    2,138 
Inventory write-down   263,404    576,772 
Bad debts   -    25,085 
Changes in operating assets and liabilities:          
Inventories   159,000    584,151 
Prepaids and other current assets   (520,653)   102,022 
Other non-current assets   4,908    5,507 
Accounts receivable   52,718    (107,357)
Accounts payable and accrued liabilities   (425,446)   (585,341)
Deferred rent   (16,171)   16,171 
Lease obligations   (289,302)   (317,490)
Total cash used in operating activities   (5,956,668)   (6,625,265)
           
Investing Activities          
Payment of acquisition consideration   -    (500,000)
Sale of short-term investments   42,513    - 
Purchase of short-term investments   (42,513)   - 
Purchase of property and equipment   (9,293)   (128198)
Total cash used in investing activities   (9,293)   (628,198)
           
Financing Activities          
Proceeds from private placement   4,654,042    10,680,654 
Total cash provided by financing activities   4,654,042    10,680,654 
           
(Decrease) increase in cash and cash equivalents during the period   (1,311,919)   3,427,191 
Cash and cash equivalents beginning of the period   8,912,517    6,176,866 
Cash and cash equivalents end of the period   7,600,598    9,604,057 
           
SUPPLEMENTARY CASH FLOW INFORMATION:          
Cash Paid During the Year for:          
Income taxes  $-   $11,300 
Interest  $-   $- 
           
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Fair value of warrant modification recorded as equity issuance costs  $3,508,749   $- 
Preferred investment options to its placement agent  $325,699   $691,483 
Recognition of Right-of-use asset and corresponding operating lease liability  $968,376   $- 

 

5

 

 

About InMed:

 

InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with its subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. For more information, visit www.inmedpharma.com.

 

Investor Contact:

 

Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1 604 416 0999

E: cclancy@inmedpharma.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the efficacy of INM-901, INM-901’s ability to treat Alzheimer’s, marketability and uses for INM-901, the results of further studies into INM-901 and acceleration of the development of InMed’s Alzheimer’s program; the efficacy of INM-089, INM-089’s ability to treat AMD, marketability and uses for INM-089, the results of further studies into INM-089 and the further development of InMed’s AMD program; being optimistic about the long-term growth potential in the rare cannabinoids sector; improving margins over time; expectations that the Company’s cash will be sufficient to fund its planned operating expenses and capital expenditure requirements into the fourth quarter of calendar year 2024.

 

Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.

 

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

6

 

 EX-101.SCH 3 inm-20240514.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inm-20240514_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 inm-20240514_pre.xml XBRL PRESENTATION FILE GRAPHIC 6 ex99-1_001.jpg GRAPHIC begin 644 ex99-1_001.jpg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htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
May 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 14, 2024
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code 604
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( )B!KE@'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "8@:Y8^A.3#>\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M3L,P#(=?!>7>.NT*AZCK91,GD)"8!.(6)=X6K?FCQ*C=V].&K1."!^ 8^Y?/ MGR6W*@CE([Y$'S"2P70WVMXEH<*:'8F" $CJB%:F85H ]6G24H"HK8-T\ M,9S'OH4;8(811IN^"Z@78J[^BMS N MD70*IU_)"#H'7+/KY+?59KM[9%W-ZZ;@]T75[&HNJEHTS&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "8@:Y8D.W'UI($ #"$0 & 'AL+W=O(B)I*MAC77OKEU M.B8@>^.5LZTZN29F*$LAOIF;23"L68:(A']7OL\'#8)94,4^$;SS0FV&M5R,!6]$TU,]B^\ . VH;/5^$*OM+MOMW MVU:-^*G2(CH$ T'$X_U_^G%(Q$E LWTFP#D$.!GW_HLRRCNJZ6@@Q99(\S:H MF8MLJ%DTP/'8S,I<2_B40YP>>>*=R4%#@Y1YT/ /8;?[,.=,V!/=$;MU11S+ M:?T8W0" G,+)*9Q,KHE1D'_=I=(2YNF_,J"]0JMY8?R)\S9ROB:F/[H2?0BEJLM@EK P.#^_5OR 0K1RBA:JX0!!D%/_TV@A/-^?I7L+SS-;<%#:D;$JCTCSA.I/IT_B. MS![#MF[!-*#&94T)),X8!_D"]N58>)*%N2N MZ_2:3@_!ZN=8_4NP%O2#3 )@XRONT\S(S\\LKMCOU>V6TW.Z?03/M@KCM"X! MG,2^D(F0&=L5F6M8"41(XHD4$@IY%4'IC%>HNS8&>>+N]B60;A" *:JKXP5Y MA/?(U[B<#)>KLD#59K':P6CE]"(,/*B(]BHH7\B]\P= MY'4AMG$I-2[W2F&>TD^][D>XHAW8N*'_#)?/^DR*=Q[[Y7G%-6\]#*UH$C;N M\I_RMJ_#4B!,4 M/<#!77HF6=V']#!8\OO](6S18"?[=;4JG[\*O4JRPO@=W*4_D4V42H&L$A"7 MK00\V?'CAKS@&G9I8D5LY_?E'V3._!3JK=2G*I1,?<*V8+ZA8#!7)!8DH9*\ MTS!%20NS=W!C7D@:F(J;[Z*E**VW"@'8OF$@A;4[N"$?[.1>X^CIA0$^7PFACS?FW)__;#/Z M'U!+ P04 " "8@:Y8GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67= MA['-HN6/O.-%Q[I#)6 M,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-? MRA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@# ME_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\ M;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/! MI!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V, MD_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]? M\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD M\%G'!QR>(W?#$T%^@2O M&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R M^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%N MV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@/ M/GL?)=-[*CG_5U/\!%!+ P04 " "8@:Y8EXJ[', 3 @ "P %]R M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_: MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$ MVV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( )B!KEBJQ"(6,P$ "(" M / >&PO=V]R:V)O;VLN>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V- MB??0NM0BB2O'A8VOG]NJ&M)>]I31=B;FJ19IZFL:C! MVWA'#02=5,3>BD(^IK%AL&6L <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$ M2_R==S Y8\0#.I3OW/1W!R;Q&-#C%B/%*0:S;%4S.Y68R#/; M@L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V M&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N M\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG M5LJ]AU>RY1AQ_)[E#U!+ P04 " "8@:Y8)!Z;HJT #X 0 &@ 'AL M+U]R96QS+W=O[IFBG#S^0W1UW6E\./VR./ / M,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G M>1,)KM\,<'AT_@%02P,$% @ F(&N6&60>9(9 0 SP, !, M !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 ! M8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB M'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T.EY&TWP39G M8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9# ML9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/ MN]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DW MY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4 " "8 M@:Y8!T%-8H$ "Q $ @ $ 9&]C4')O<',O87!P M+GAM;%!+ 0(4 Q0 ( )B!KECZ$Y,-[P "L" 1 " M :\ !D;V-0&UL4$L! M A0#% @ F(&N6)#MQ]:2! PA$ !@ ("!#@@ 'AL M+W=O 2 K !;0V]N=&5N=%]4>7!E&UL4$L%!@ ) D /@( "H4 $! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityAddressStateOrProvince, dei:EntityIncorporationStateCountryCode - ea0206088-8k_inmed.htm 21, 22 ea0206088-8k_inmed.htm inm-20240514.xsd inm-20240514_lab.xml inm-20240514_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ea0206088-8k_inmed.htm": { "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20240514", "dts": { "inline": { "local": [ "ea0206088-8k_inmed.htm" ] }, "schema": { "local": [ "inm-20240514.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "inm-20240514_lab.xml" ] }, "presentationLink": { "local": [ "inm-20240514_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 5, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://inmedpharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0206088-8k_inmed.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-14", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "ea0206088-8k_inmed.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://inmedpharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001213900-24-042944-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-24-042944-xbrl.zip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end XML 19 ea0206088-8k_inmed_htm.xml IDEA: XBRL DOCUMENT 0001728328 2024-05-14 2024-05-14 iso4217:USD shares iso4217:USD shares false 0001728328 A1 BC CA 8-K 2024-05-14 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street Vancouver V6C 1B4 604 669-7207 false false false false Common Shares, no par value INM NASDAQ true false